Overview

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Status:
Terminated
Trial end date:
2021-05-28
Target enrollment:
Participant gender:
Summary
A Trial of GC4419 in Patients with Critical Illness due to COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Galera Therapeutics, Inc.
Treatments:
Avasopasem manganese